1 – 36 of 36
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein
(
- Contribution to journal › Article
-
Mark
Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
(
- Contribution to journal › Article
- 2017
-
Mark
Ponezumab in mild-to-moderate Alzheimer's disease : Randomized phase II PET-PIB study
2017) In Alzheimer's and Dementia: Translational Research and Clinical Interventions 3(3). p.393-401(
- Contribution to journal › Article
- 2016
-
Mark
A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Serum neurofilament light protein predicts clinical outcome in traumatic brain injury
(
- Contribution to journal › Article
- 2015
-
Mark
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer's Disease: A Randomized, Placebo-Controlled Study.
(
- Contribution to journal › Article
- 2014
-
Mark
The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?
(
- Contribution to journal › Article
- 2013
-
Mark
Evaluating Amyloid-beta Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia
(
- Contribution to journal › Article
-
Mark
Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia
(
- Contribution to journal › Article
- 2012
-
Mark
Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid Profiles of Amyloid beta-Related Biomarkers in Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Safety, tolerability, and antibody response of active A beta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
(
- Contribution to journal › Article
-
Mark
A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease
(
- Contribution to journal › Article
- 2011
-
Mark
Ubiquitin Carboxyl-Terminal Esterase L1 (UCHL1) S18Y Polymorphism In Patients With Cataracts
(
- Contribution to journal › Article
- 2010
-
Mark
No Association of VEGF Polymorphims with Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Kinesin Light Chain 1 Gene Haplotypes in Three Conformational Diseases
(
- Contribution to journal › Article
-
Mark
Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract
(
- Contribution to journal › Article
- 2009
-
Mark
Long-term rivastigmine treatment in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
Longitudinal study of CSF biomarkers in patients with Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
(
- Contribution to journal › Article
- 2008
-
Mark
Association of complement factor HY402H gene polymorphism with Alzheimer's disease
(
- Contribution to journal › Article
- 2007
-
Mark
Longitudinal stability of CSF biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
(
- Contribution to journal › Article
- 2006
-
Mark
New regression models for long-term cognitive change in Donepezil treated Alzheimer patients.
2006) 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
-
Mark
2-års resultat av rivastigmin (Exelon®) behandling vid Alzheimers sjukdom i klinisk vardag.
2006) Läkarstämman 2006(
- Contribution to conference › Poster
-
Mark
Two-year outcome of Galantamine treatment in Alzheimer’s disease in a routine clinical setting.
2006) 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
-
Mark
Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms
(
- Contribution to journal › Article
- 2005
-
Mark
Analysis of the heterogeneity in treatment response to Donepezil in Alzheimer’s disease conclusions from the Swedish Alzheimer Treatment Study Group.
(
- Contribution to conference › Poster
- 2003
-
Mark
Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease
(
- Contribution to journal › Article
- 2002
-
Mark
Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins
(
- Contribution to journal › Article
-
Mark
Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients
(
- Contribution to journal › Article